General Information
| Application | Inhibitor |
|---|
| Description | E7080 (Lenvatinib) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3. |
|---|
| Cas NO. | 417716-92-8 |
|---|
| Purity | ≥99% |
|---|---|
| Molecular Weight | 426.85 |
| Formula | C21H19ClN4O4 |
| Solubility |
DMSO : 40 mg/mL Ethanol : Insoluble Water : Insoluble |
|---|
| Alias | N/A |
|---|
| Target / IC50 |
VEGFR1/FTL1 : 22 nM VEGFR2/KDR : 4.0 nM VEGFR3/FLT4 : 5.2 nM FGFR1 : 46 nM PDGFRβ : 39 nM |
|---|
| Storage |
Powder : -20°C for 3 years |
|---|
|
|
1 mg |
5 mg |
10 mg |
|
|
1 mM |
2.3427 mL | 11.7137 mL | 23.4274 mL | |
| 5 mM | 0.4685 mL | 2.3427 mL | 4.6855 mL | |
| 10 mM | 0.2343 mL | 1.1714 mL | 2.3427 mL | |
.png)